Gly Gly Gly Gly Ser | 2543-43-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Gly Gly Gly Gly Ser
• 英文别名: Gly · Gly · Gly · Gly · Ser；L-Serine, glycylglycylglycylglycyl-；(2S)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid
• CAS: 2543-43-3
• 化学式: C₁₁H₁₉N₅O₇
• 分子量: 333.301
• InChiKey: HKZAAJSTFUZYTO-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6.7
• 重原子数：
  23
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  200
• 氢给体数：
  7
• 氢受体数：
  8

文献信息

• Antibodies
  申请人：Oxford Biomedica (UK) Limited

  公开号：EP2161286A1

  公开（公告）日：2010-03-10

  The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applicatrions.

  本文描述了一种能够识别疾病相关分子（DAM）的 ScFv Ab（ScFv Ab）在制造预防和/或治疗与 DAM 相关疾病的药物中的应用。ScFv Ab 可用于治疗、诊断和预后。
• Antibody derivatives
  申请人：MEDIMMUNE LIMITED

  公开号：US10202447B2

  公开（公告）日：2019-02-12

  The invention relates inter alia to a bivalent, bispecific construct comprising an anti-IL-6 antibody, or derivative thereof, and an anti-IL-23 antibody, or derivative thereof and its use in therapy. The invention also relates to useful anti-IL-6 antibodies and anti-IL-23 antibodies.

  本发明主要涉及一种由抗IL-6抗体或其衍生物和抗IL-23抗体或其衍生物组成的双价、双特异性构建物及其在治疗中的应用。本发明还涉及有用的抗IL-6抗体和抗IL-23抗体。
• RNA viruses expressing IL-12 for immunovirotherapy
  申请人：DEUTSCHES KREBSFORSCHUNGSZENTRUM

  公开号：US10344067B2

  公开（公告）日：2019-07-09

  The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding an IL-12 polypeptide, wherein said IL-12 polypeptide is an IL-12 fusion polypeptide comprising a p35 subunit of an IL-12 and a p40 subunit of an IL-12; to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.

  本发明涉及一种副粘病毒科重组病毒，其包含至少一种编码IL-12多肽的可表达多核苷酸，其中所述IL-12多肽是IL-12融合多肽，其包含IL-12的p35亚基和IL-12的p40亚基；本发明还涉及编码本发明的多核苷酸以及包含本发明的试剂盒。此外，本发明还涉及一种治疗癌症患者癌症的方法，包括使所述患者与本发明的副粘病毒科重组病毒接触，从而治疗癌症患者的癌症。
• Targeting intracellular target-binding determinants with intracellular antibodies
  申请人：The United States of America as represented by the Department of Veterans Affairs

  公开号：US10683363B2

  公开（公告）日：2020-06-16

  The invention provides a method for inhibiting an intracellular target in a cell with a bispecific antibody comprising contacting the cell with a bispecific antibody having a first Fv fragment with a cell-penetrating determinant and a second Fv fragment with an intracellular target-binding determinant under suitable conditions so that the first Fv fragment causes the bispecific antibody to enter the cell and the second Fv fragment binds the intracellular target in the cell and thereby inhibiting the intracellular target.

  本发明提供了一种用双特异性抗体抑制细胞内靶点的方法，该方法包括在适当的条件下，将具有带细胞穿透决定簇的第一Fv片段和带细胞内靶点结合决定簇的第二Fv片段的双特异性抗体与细胞接触，使第一Fv片段使双特异性抗体进入细胞，第二Fv片段与细胞内靶点结合，从而抑制细胞内靶点。
• Lym-1 and Lym-2 targeted CAR cell immunotherapy
  申请人：Epstein Alan L.

  公开号：US10711064B2

  公开（公告）日：2020-07-14

  CAR cells targeting and antibodies human HLA-DR are described as a new method of cancer treatment. It is proposed that HLA-DR CAR cells are safe and effective in patients and can be used to treat human tumors expressing the HLA-DR.

  以人类 HLA-DR 为靶标和抗体的 CAR 细胞被描述为一种新的癌症治疗方法。研究提出，HLA-DR CAR 细胞对患者安全有效，可用于治疗表达 HLA-DR 的人类肿瘤。